Xenon Pharmaceuticals Inc (XENE)
40.50
+0.40
(+1.00%)
USD |
NASDAQ |
Apr 26, 16:00
40.54
+0.04
(+0.10%)
After-Hours: 20:00
Xenon Pharmaceuticals Cash from Financing (TTM): 353.52M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 353.52M |
September 30, 2023 | 29.51M |
June 30, 2023 | 0.705M |
March 31, 2023 | 270.60M |
December 31, 2022 | 278.47M |
September 30, 2022 | 602.42M |
June 30, 2022 | 606.48M |
March 31, 2022 | 336.70M |
December 31, 2021 | 447.54M |
September 30, 2021 | 123.64M |
June 30, 2021 | 118.88M |
March 31, 2021 | 102.05M |
December 31, 2020 | 85.80M |
September 30, 2020 | 113.18M |
June 30, 2020 | 113.20M |
March 31, 2020 | 129.93M |
December 31, 2019 | 27.52M |
September 30, 2019 | 0.121M |
June 30, 2019 | 77.53M |
Date | Value |
---|---|
March 31, 2019 | 111.53M |
December 31, 2018 | 111.59M |
September 30, 2018 | 118.45M |
June 30, 2018 | 41.02M |
March 31, 2018 | 7.015M |
December 31, 2017 | 7.07M |
September 30, 2017 | 0.225M |
June 30, 2017 | 24.06M |
March 31, 2017 | 24.09M |
December 31, 2016 | 23.96M |
September 30, 2016 | 23.95M |
June 30, 2016 | 0.147M |
March 31, 2016 | 0.195M |
December 31, 2015 | 0.278M |
September 30, 2015 | 42.66M |
June 30, 2015 | 42.06M |
March 31, 2015 | 41.64M |
December 31, 2014 | 41.12M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.121M
Minimum
Sep 2019
606.48M
Maximum
Jun 2022
200.94M
Average
118.88M
Median
Jun 2021
Cash from Financing (TTM) Benchmarks
Acasti Pharma Inc | 7.359M |
Aurinia Pharmaceuticals Inc | -5.13M |
Edesa Biotech Inc | 2.224M |
Lexaria Bioscience Corp | 6.862M |
ESSA Pharma Inc | 0.1129M |